Kajian Lebar Bangunan Pelimpah Tipe Lengkung terhadap Elevasi Muka Banjir (Studi Kasus Waduk Tenayan)

Tenayan reservoir is a facility that included in the planning of infrastructure development Pekanbaru city government offices were built to meet the needs of the office of the raw water. Tenayan Reservoir drainage system is part of DAS system of Siak where natural systems there is a watershed Tenayan. In a study on the construction of the reservoir, spillway is an important study that is based on considerations of topography, hydrology and hydraulics. In this study the hydrological analysis to get the flood discharge design using Nakayau HSS. Further studies conducted by calculating the width of spillway flood search through the spillway (spillway) for various types of straight spillway with a width of 25 m and type of arch spillway with a variation of the radius of 12,5 m, 15 m, 20 m and 25 m in order to obtain flood level elevation for various the variations in the hydrological analysis result obtained Tenayan flood discharge design period of 20 years of rainfall data (1994-2013) for 100 year return period amounted to 182.063 m3 / second using Nakayasu HSS. By using the design flood discharge of the obtained spillway flood level elevation (crest elevation +20 m) for various types of overflow proportional to the width of 25m is +21.787 m and for overflow arch with a variation of the radius of 12,5m, 15m, 20m and 25 m respectively +21.399 m, +21.650 m, + 21,725m and + 21,750 m

The Vlasov limit and its fluctuations for a system of particles which interact by means of a wave field

In two recent publications [Commun. PDE, vol.22, p.307--335 (1997), Commun. Math. Phys., vol.203, p.1--19 (1999)], A. Komech, M. Kunze and H. Spohn studied the joint dynamics of a classical point particle and a wave type generalization of the Newtonian gravity potential, coupled in a regularized way. In the present paper the many-body dynamics of this model is studied. The Vlasov continuum limit is obtained in form equivalent to a weak law of large numbers. We also establish a central limit theorem for the fluctuations around this limit.Comment: 68 pages. Smaller corrections: two inequalities in sections 3 and two inequalities in section 4, and definition of a Banach space in appendix A1. Presentation of LLN and CLT in section 4.3 improved. Notation improve

Role of organic soil amendment of paramagnetic humus and compost for rehabilitation of post tin-mined tropical land

Open tin mining on tropical Bangka Island, Indonesia exposed heavy metals that had become a major cause of land degradation and severe local_global environmental damage. The goal of this study is to accelerate the remediation of degraded ecosystems in tin mined land, and thereby promote sustainable land use and environmental productivity. To the tailings of a former tin mined on Bangka Island, we applied an organic amendment comprising compost and paramagnetic humus at dosages of 0%, 5%, and 10%, and analyzed the results using a factorial completely randomized design (FCRD). We found the soil from the former tin mining site to be acidic (pH 5.34) and dominated by sand particles (88%) with a very low cation exchange capacity. The soils also had a very low nutrient content (available and total-N, P, K, Ca, Mg), high toxicity levels of Zn, Cu, B, Cd and Ti, as well low toxicity levels of B, Zn, Cu, Ti, Cd. Organic soil amendments of organic paramagnetic materials and compost can improve soil quality by increasing the pH, the high availability of P and K and the cation exchange capacity, as well as maintain low toxicity. The growth (high, diameter, biomass, top-root ratio) of the exotic pioneer plant Reutealis trisperma increases the quality of soils to which proper soil amendments have been applied. The overall concept and appropriate technology for rehabilitating the ecosystem of degraded tin-mined land in tropical regions which serve as the world’s lungs, will strongly contribute to the development of a healthy and sustainable environment for all life on this plane

A mixed method, phase 2 clinical evaluation of a novel device to treat postpartum haemorrhage

Background: We evaluated the safety, efficacy, and acceptability of a new device designed to facilitate uterine compression in women with postpartum haemorrhage (PPH). Methods: A prospective, phase two clinical device trial with concurrent qualitative study, conducted in a UK consultant obstetric unit. The device was used in addition to standard care in women unresponsive to initial oxytocin therapy. The primary effectiveness outcome was additional blood loss of over 1000mls, whilst safety was assessed through adverse events. Interviews assessed device feasibility and acceptability, and were analysed using framework analysis. Results: We recruited 57 women with clinical PPH after vaginal birth; 67% were primiparous and 47% had undergone operative birth. All but two (96%) had atony as a cause of the haemorrhage; in addition, 30% also had bleeding from lacerations and 11% had retained tissue. After device use, only one woman had additional blood loss over 1000mls, although 3 women (7%) needed a Bakri balloon and 14% received a blood transfusion. All but one clinician felt that the device was easy to use. Clinicians stated that the device assisted management in 85% of cases. All 56 women who responded stated that if they bled in a future birth they would want the device to be used again. There were no serious adverse events related to the device. However, 3 events were judged as 'possibly' being caused by the device - 2 minor vaginal grazes and one postnatal episiotomy infection and breakdown. Lax vaginal tissue complicated the use of the device in three women. In 47 interviews, participants, birth partners, clinician users and attending midwives viewed the device positively. Clinicians found it useful as a way of stopping blood loss and as an aid to diagnose the source of bleeding. Conclusions: The PPH Butterfly may provide a rapid, acceptable and effective treatment for postpartum haemorrhage

brainlife.io: A decentralized and open source cloud platform to support neuroscience research

Neuroscience research has expanded dramatically over the past 30 years by advancing standardization and tool development to support rigor and transparency. Consequently, the complexity of the data pipeline has also increased, hindering access to FAIR data analysis to portions of the worldwide research community. brainlife.io was developed to reduce these burdens and democratize modern neuroscience research across institutions and career levels. Using community software and hardware infrastructure, the platform provides open-source data standardization, management, visualization, and processing and simplifies the data pipeline. brainlife.io automatically tracks the provenance history of thousands of data objects, supporting simplicity, efficiency, and transparency in neuroscience research. Here brainlife.io's technology and data services are described and evaluated for validity, reliability, reproducibility, replicability, and scientific utility. Using data from 4 modalities and 3,200 participants, we demonstrate that brainlife.io's services produce outputs that adhere to best practices in modern neuroscience research

Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

Background and purpose: Prospectively collected data comparing the safety and effectiveness of individual non-vitamin K antagonists (NOACs) are lacking. Our objective was to directly compare the effectiveness and safety of NOACs in patients with newly diagnosed atrial fibrillation (AF). Methods: In GLORIA-AF, a large, prospective, global registry program, consecutive patients with newly diagnosed AF were followed for 3 years. The comparative analyses for (1) dabigatran vs rivaroxaban or apixaban and (2) rivaroxaban vs apixaban were performed on propensity score (PS)-matched patient sets. Proportional hazards regression was used to estimate hazard ratios (HRs) for outcomes of interest. Results: The GLORIA-AF Phase III registry enrolled 21,300 patients between January 2014 and December 2016. Of these, 3839 were prescribed dabigatran, 4015 rivaroxaban and 4505 apixaban, with median ages of 71.0, 71.0, and 73.0 years, respectively. In the PS-matched set, the adjusted HRs and 95% confidence intervals (CIs) for dabigatran vs rivaroxaban were, for stroke: 1.27 (0.79–2.03), major bleeding 0.59 (0.40–0.88), myocardial infarction 0.68 (0.40–1.16), and all-cause death 0.86 (0.67–1.10). For the comparison of dabigatran vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 1.16 (0.76–1.78), myocardial infarction 0.84 (0.48–1.46), major bleeding 0.98 (0.63–1.52) and all-cause death 1.01 (0.79–1.29). For the comparison of rivaroxaban vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 0.78 (0.52–1.19), myocardial infarction 0.96 (0.63–1.45), major bleeding 1.54 (1.14–2.08), and all-cause death 0.97 (0.80–1.19). Conclusions: Patients treated with dabigatran had a 41% lower risk of major bleeding compared with rivaroxaban, but similar risks of stroke, MI, and death. Relative to apixaban, patients treated with dabigatran had similar risks of stroke, major bleeding, MI, and death. Rivaroxaban relative to apixaban had increased risk for major bleeding, but similar risks for stroke, MI, and death. Registration: URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01468701, NCT01671007. Date of registration: September 2013

Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation. the GLORIA-AF registry

Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores >2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2 scores >2 than to patients with lower scores. Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and ≥1 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of the VKA prescription among anticoagulated patients with the baseline SAMe-TT2R2 score >2 and ≤ 2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) patients were prescribed VKA and 12,637 (72.4%) patients an NOAC: 11,884 (68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581 (32.0%) patients had scores >2. The proportion of patients prescribed VKA was 28.0% among patients with SAMe-TT2R2 scores >2 and 27.5% in those with scores ≤2. Conclusions: The lack of a clear association between the SAMe-TT2R2 score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs as well as to the absence of trial evidence that an SAMe-TT2R2-guided strategy for the selection of the type of anticoagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial. Clinical trial registration: URL: https://www.clinicaltrials.gov//Unique identifier: NCT01937377, NCT01468701, and NCT01671007